Ulisse Biomed S.p.A.

BST:8XX Stock Report

Market Cap: €16.9m

Ulisse Biomed Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Nicola Basile

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Nicola Basile (45 yo)

less than a year

Tenure

Mr. Nicola Basile is CEO & Director of Ulisse Biomed S.p.A. from March 2024.

Board Members

NamePositionTenureCompensationOwnership
Nicola Basile
CEO & Directorless than a yearno datano data
Bruna Marini
Co-founderno datano datano data
Carlo Montenovesi
Executive Directorless than a yearno datano data
Robert Gallo
Member of Scientific Boardno datano datano data
Gordon Whiteley
Member of Scientific Boardno datano datano data
Alberto Camilotti
Chairman of the Board of Statutory Auditorsno datano datano data
Joseph Kates
Chairman of Scientific Boardno datano datano data
Lawrence Banks
Member of Scientific Boardno datano datano data
Davide Zella
Member of Scientific Boardno datano datano data
Clara Carbone
Standing Auditorless than a yearno datano data
Stefano Priore
Non-Executive Chairmanless than a yearno datano data
Aurora Agostini
Independent Directorless than a yearno datano data

0.8yrs

Average Tenure

53yo

Average Age

Experienced Board: 8XX's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ulisse Biomed S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marco GrecoValueTrack
Valentina RomitelliValueTrack